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Shunt infection is a major complication affecting approximately 10% of procedures. Propionibacterium acnes,
an anaerobic skin bacterium, is increasingly recognized as a shunt pathogen, causing up to 14% of infections.
Though susceptible to penicillin and cephalosporins, P. acnes shunt infections are not preventable by means
of perioperative prophylaxis, due to poor cerebrospinal fluid penetration. Antimicrobial shunts with activity
against staphylococci are available, but their activity against P. acnes is unknown, and the study was designed
to determine this. Three methods of evaluation were used in order to determine the emergence of resistance
when exposure is to high inocula for long periods, the time taken to kill 100% of the bacteria attached to the
shunt, and the duration of activity under constant flow conditions with repeated bacterial challenge. Despite
repeated exposure to high bacterial inocula over 70 days, no resistance was seen. The time taken to kill all
attached bacteria, 96 h, was twice that taken to kill attached staphylococci. Nevertheless, under constant flow
conditions with repeated challenges, the antimicrobial catheters resisted colonization by P. acnes for 56 days.
Using tests that were designed to be clinically predictive when done together, the results suggest that the
antimicrobial catheters will be able to prevent colonization of hydrocephalus shunts by P. acnes.
Hydrocephalus is the pathological accumulation of cerebro-
spinal fluid (CSF) in the cerebral ventricles and is caused by a
variety of factors, such as intrauterine infection, meningitis,
hemorrhage, and tumors. The standard treatment is surgical
insertion of a shunt, a silicone tubular device that drains CSF
from the cerebral ventricles to another body site, usually the
peritoneal cavity. Infection is a serious complication of shunt-
ing, the incidence ranging from less than 1% to over 15%, with
an overall incidence of about 10% (13, 18). Shunt infection in
the United States has been estimated to account for more than
$100 million in national health care expenditure annually (29).
The causative bacteria are usually of skin origin, and coagu-
lase-negative staphylococci (CoNS) predominate. However, a
proportion of shunt infections, reported to be approximately
14%, is caused by Propionibacterium acnes, also a normal skin
inhabitant (1, 4, 30). This organism is anaerobic and slow
growing and often fails to be detected. Like CoNS, P. acnes
adheres to the inner surfaces of the shunt catheters and devel-
ops a biofilm (4, 11), leading to antibiotic treatment failure and
necessitating shunt removal.
Although antimicrobial prophylaxis is almost universally
used, its role in reducing the incidence of shunt infections
remains controversial. Systemic antibiotics penetrate the
blood-cerebrospinal fluid barrier poorly in the absence of in-
flammation (2, 17, 20, 21, 22). The use of intraventricular
antibiotics to overcome this has not been successful (6, 32),
with the possible exception of the combination of intraventric-
ular gentamicin and vancomycin, which has been reported to
significantly reduce the incidence of perioperative shunt infec-
tion (27). However, this result remains to be confirmed.
An alternative method of preventing infection involves the
use of antimicrobial shunts (8). These are impregnated with
rifampin and clindamycin (Bactiseal; Codman and Shurtleff,
Inc., Raynham, MA) and provide a duration of activity of
approximately 50 days (9). Bacterial colonization on both inner
and outer surfaces is prevented (5). Clinical trials of various
quality and design have demonstrated a reduction in the rate of
infection due to Gram-positive bacteria (14, 16, 24, 26), but the
activity of these shunt catheters against P. acnes has not been
determined. The aims of this research were to investigate the
activity of antimicrobial shunt catheters against P. acnes and
the duration of that activity and to determine whether expo-
sure to the catheters caused the emergence of resistance.
MATERIALS AND METHODS
Test strains. Three clinical isolates of P. acnes, all from proven arthroplasty
infections in different patients, were characterized by established methods, in-
cluding the Rapid ID 32 A (bioMe´rieux, Marcy-l’Etoile, France) system. All
three had different identification profiles by the Rapid ID 32 A system
(0403330404, 0003330604, and 0003120604). They all showed the same MICs of
rifampin (0.016 mg/liter) and clindamycin (0.0125 mg/liter), measured using agar
incorporation with brucella blood agar (Oxoid, Basingstoke, United Kingdom).
All have been shown to develop biofilms on biomaterials (4). They were main-
tained under anaerobic conditions at 37°C on sheep blood agar (BA) plates
(Oxoid).
Shunt catheters. Plain silicone shunt catheters for use as controls and impreg-
nated catheters (Bactiseal) were donated by Codman. The catheters are impreg-
nated with 0.054% (wt/wt) rifampin and 0.15% (wt/wt) clindamycin hydrochlo-
ride.
SPTT. The serial plate transfer test (SPTT) was performed to assess the
duration of antimicrobial activity of impregnated catheters against P. acnes and
to detect resistance. Three sets of BA plates were each seeded (0.2 ml of 107
CFU/ml) with one of three strains of P. acnes, and three 1-cm segments of
catheter were placed on the surface of each and incubated anaerobically. The
segments were removed and placed on fresh plates every 7 days. Each segment
was indelibly marked to ensure that the same surface was in contact with the agar
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at each transfer. Upon each transfer, the zone of inhibition was measured across
the short axis. This procedure was repeated until no zones of inhibition were
seen. Irrespective of zone size, the presence of any bacteria immediately in
contact with the catheter was noted to evaluate the development of “paradoxi-
cal” bacterial resistance, seen when bacteria attached to the antibacterial bio-
material develop a biofilm on its surface yet the biomaterial is surrounded by a
zone of inhibition of the same bacterium on an agar plate. This phenomenon has
been described previously (7).
tK100. The test of time taken to kill 100% attached bacteria (tK100 test) is used
to determine the time needed to kill 100% of bacteria attached to the surface of
the catheters (5). Anaerobe basal broth (ABB CM0957; Oxoid) was inoculated
with several colonies of P. acnes from an overnight BA plate of each of three
strains, and bacteria were grown at 37°C to prepare planktonic suspensions. The
optical density (OD) at 490 nm of the planktonic suspension was adjusted to 0.6
to 0.7 (107 CFU/ml). Catheter segments 1 cm long were cut longitudinally and
placed in triplicate in Eppendorf tubes containing 1 ml of the bacterial suspen-
sion and incubated anaerobically at 37°C for 1 h. They were then removed, rinsed
in 1 ml of ABB, replaced in 1 ml of 25% ABB, and incubated for 24, 48, 72, 96,
or 120 h. After each 24-h incubation period, catheter segments for further
incubation were removed, rinsed in 1 ml of ABB, and placed in 1 ml fresh 25%
ABB. At the end of each 24-h period, three catheters were removed, rinsed, and
sonicated for 20 min (Ultrawave Ltd., Cardiff, United Kingdom) at 50 Hz to
remove the adhered bacteria. The sonicates were cultured anaerobically on BA
for 72 to 96 h at 37°C, and any colonies were counted. Each strain was tested in
triplicate on each occasion.
IVC. An in vitro challenge (IVC) model designed to simulate in-use conditions
(temperature, hydration, flow rate) (9) was used to test the ability of P. acnes to
colonize the luminal surface of impregnated catheters and plain silicone cathe-
ters. Briefly, test catheters were connected in triplicate to inflow and outflow
tubes and placed in a chamber filled with sodium thioglycolate (0.5 g/dl) to
maintain anaerobic conditions and maintained at 37°C. The catheters were then
constantly perfused with ABB using a peristaltic pump at a flow rate of 20 ml/h
(the average CSF production rate) and challenged luminally every 2 weeks with
1 ml of 107 CFU/ml of one of the P. acnes strains. The plain control catheters
were changed before each new challenge as they all became colonized. Samples
of control catheters were fixed in cold acetone and viewed by scanning electron
microscopy (SEM) to confirm biofilm production. Only one strain was tested by
this method, as they all appeared to have similar characteristics and the method
is time-consuming and labor-intensive. Effluent samples were taken from the
outlet tubing daily for quantitative culture. This method determined the ability of
the catheters to resist repeated bacterial challenge under flow conditions at 37°C.
The protocol of repeated challenge was intended to establish the duration of
protective activity and was not aimed at simulating clinical practice, where such
multiple bacterial challenges would be unlikely to occur. Similarly, the ABB used
to perfuse the catheters was chosen instead of artificial CSF in order to maximize
bacterial survival. All manipulations were carried out under strict aseptic condi-
tions to avoid contamination. All isolates were fully identified, and their MICs of
rifampin and clindamycin were confirmed.
RESULTS
Serial plate transfer test. The initial mean diameter of in-
hibition zone of the antimicrobial catheter segments in the
SPTT was 44.7 mm, and the mean final diameter after 70 days
was 11.5 mm (Fig. 1). No paradoxical or other resistance was
found.
tK100 assay. The time taken to kill all P. acnes, expressed as
the duration of viability of bacteria attached to control and
antimicrobial catheters, is shown in Fig. 2, which is a repre-
sentative result for the three strains. For all three strains, all
attached bacteria were killed by 96 h and did not regrow.
Attached bacteria remained viable in the control catheters
throughout the test period.
In vitro challenge. The IVC results shown in Fig. 3 demon-
strate that the antimicrobial catheters resisted bacterial chal-
FIG. 1. Serial plate transfer test (SPTT) results for the antimicro-
bial shunt catheter against three P. acnes strains are shown. There was
no significant difference among the results (P  0.47). Filled squares,
filled circles, and filled triangles represent the three strains, each tested
in triplicate. Prolonged antimicrobial activity of up to 70 days was
demonstrated for all three strains without any development of resis-
tance.
FIG. 2. The antimicrobial shunt catheters achieved killing of 100%
attached bacteria against P. acnes strains at 96 h (tK100) (P  0.05).
Squares, circles, and triangles represent the three strains, each tested
in triplicate. Filled symbols, plain control shunt catheters; open sym-
bols, antimicrobial shunt catheters.
FIG. 3. During the in vitro challenge (IVC), unlike the controls, the
antimicrobial shunt catheter (open circles) protected against P. acnes
colonization for 5 successive challenges up to 56 days (P  0.05) but
failed the 70-day challenge, becoming colonized. After each challenge
period of 14 days, the colonized control catheter (filled circles) was
removed and replaced with a fresh catheter. Catheters were tested in
triplicate.
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lenge without becoming colonized for 56 days but failed the
next challenge at 70 days. All catheters were cleared of P. acnes
between days 6 and 12 after each challenge except the last. All
plain controls became colonized with the challenge strain, as
shown by culture and SEM.
DISCUSSION
P. acnes is now a recognized pathogen in neurosurgery (23,
28), often giving rise to infections with delayed presentation (3,
12). Shunt infections due to P. acnes bacteria, also often with
delayed presentation, have been reported (1, 4, 30, 31). De-
spite their late clinical presentation, it is reasonable to assume
that, like Staphylococcus epidermidis, P. acnes bacteria gain
access to the shunt at insertion or at a subsequent revision, and
such infections are therefore preventable. P. acnes is almost
always fully susceptible to penicillin, but as with many other
antimicrobials, cerebrospinal fluid concentrations of penicillin
after a single intravenous injection are too low to be of pro-
phylactic value (15). The alternative approach of using an
antimicrobial shunt catheter accepts that skin bacteria will
inevitably gain access to the shunt lumen in most patients but
proposes that they can be prevented from colonizing the shunt
by the antimicrobial activity of the catheter. Such a catheter
was first described in 1989 (8) and has since been developed for
clinical use as the Bactiseal catheter used here. The time taken
for these catheters to kill all staphylococci that become at-
tached to their surfaces is now known to be approximately 48 h
(5). The low rate of kill is considered to be due to the change
in bacterial phenotype that is known to occur upon the attach-
ment of the bacteria to a surface (25), and it is therefore
essential that any preclinical evaluation of such catheters in-
cludes testing for activity against attached rather than plank-
tonic bacteria. Here we have shown that the time taken for the
catheters to kill all attached P. acnes bacteria is twice as long as
that for S. epidermidis bacteria, and this might be related to the
lower growth rate of the former. However, all bacteria were
eventually killed. Similarly, the in vitro challenge (IVC) test
showed that the antimicrobial catheters resisted P. acnes col-
onization for 56 days, similar to other Gram-positive bacteria
(9), but that P. acnes cleared more slowly from the challenged
catheters than staphylococci (10 to 11 days versus 2 to 3 days).
The emergence of resistance in the serial plate transfer test
usually takes the form of bacterial growth on the surface of the
catheter segment, despite there being a large zone of inhibi-
tion. This “paradoxical” resistance is sometimes seen after
exposure to antimicrobial biomaterials containing single agents
and is thought to be due to inhibited but viable bacteria at-
taching to the catheter material at the time of transfer and
developing a biofilm, thus becoming phenotypically nonsuscep-
tible (7). In clinical use, this would not only lead to failure of
the antimicrobial catheter and to infection but would also
increase the risk of emergence of mutational resistance. No
resistance, paradoxical or otherwise, was seen on continuous
exposure to high inocula over 70 days in the SPTT. Neither was
any increase in MIC seen after exposure to the catheters, as
measured by agar incorporation.
Only one other antimicrobial shunt catheter is commercially
available (Silverline; Spiegelberg GmbH and Co., Hamburg,
Germany), and this shunt contains near-nanoparticulate silver.
Investigations using techniques similar to those described here
have shown no antimicrobial activity of this shunt against P.
acnes (10). Several antimicrobial catheters are available for
temporary external ventricular drains (19, 33), but P. acnes is
not a problem for these. To our knowledge, no other antimi-
crobial catheter materials have been tested for activity against
P. acnes.
The results presented here show that the antimicrobial cath-
eters were able to eradicate all P. acnes bacteria that had
become attached to the catheters, even under flow conditions.
Based on the clinical predictivity of the tests used here in the
case of other shunt pathogens (5, 8, 9, 14, 16, 26, 29), antimi-
crobial catheters promise to give protection against P. acnes
shunt infection, extending from the perioperative to the im-
mediate postoperative period, and are likely also to prevent
late-presenting cases, as these are also contracted at initial
surgery.
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